-
Could COVID-19 mRNA vaccines cause autoimmune diseases?
(Hinzugefügt: 17.12.2020 um 08:31 Uhr)
https://www.bmj.com/content/371/bmj.m4347/rr-6
-
Interim Considerations: Preparing for the Potential Management of Anaphylaxis After COVID-19 Vaccination
(Hinzugefügt: 24.01.2021 um 09:05 Uhr)
https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html
-
Interim Considerations: Preparing for the Potential Management of Anaphylaxis After COVID-19 Vaccination
(Hinzugefügt: 24.01.2021 um 09:05 Uhr)
https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html
-
SARS-CoV-2: Laborexperimente deuten auf verminderte Schutzwirkung gegen neue Varianten hin
(Hinzugefügt: 23.01.2021 um 09:04 Uhr)
https://www.aerzteblatt.de/nachrichten/120379/SARS-CoV-2-Laborexperimente-deuten-auf-verminderte-Schutzwirkung-gegen-neue-Varianten-hin
-
Unilateral axillary lymphadenopathy in the setting of COVID-19 vaccine
(Hinzugefügt: 21.01.2021 um 11:11 Uhr)
https://www.clinicalimaging.org/article/S0899-7071(21)00020-6/fulltext?dgcid=raven_jbs_aip_email
-
COVID-19 Vaccine-Linked Adenopathies Could Mimic Breast Malignancies
(Hinzugefügt: 21.01.2021 um 11:10 Uhr)
https://www.diagnosticimaging.com/view/covid-19-vaccine-linked-adenopathies-could-mimic-breast-malignancies
-
Vaccinating Children against Covid-19 — The Lessons of Measles
(Hinzugefügt: 21.01.2021 um 10:55 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMp2034765
-
Covid-19 Vaccine Resource Center
(Hinzugefügt: 21.01.2021 um 08:56 Uhr)
https://www.nejm.org/covid-vaccine
-
Realising the potential of SARS-CoV-2 vaccines—a long shot?
(Hinzugefügt: 21.01.2021 um 08:55 Uhr)
https://www.thelancet.com/action/showPdf?pii=S2213-2600%2821%2900045-X
-
The Benefits of Vaccinating With the First Available COVID-19 Coronavirus Vaccine
(Hinzugefügt: 20.01.2021 um 08:42 Uhr)
https://www.ajpmonline.org/article/S0749-3797(21)00021-0/fulltext
-
SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn
(Hinzugefügt: 19.01.2021 um 06:57 Uhr)
https://www.acpjournals.org/doi/10.7326/M21-0111#.YAYUAKI1Hfg.twitter
-
PDF [409 KB] Figures Save Share Reprints Request The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines
(Hinzugefügt: 15.01.2021 um 14:49 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00085-4/fulltext
-
Depression and Stress Could Dampen Efficacy of COVID-19 Vaccines: Interventions and Health Behavior Changes Could Boost Immunity
(Hinzugefügt: 15.01.2021 um 07:06 Uhr)
https://www.psychologicalscience.org/news/releases/2021-jan-depression-covid-vaccines.html
-
iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19
(Hinzugefügt: 15.01.2021 um 07:03 Uhr)
https://www.globenewswire.com/news-release/2021/01/12/2156927/0/en/iosBio-signs-exclusive-worldwide-licensing-agreement-granting-ImmunityBio-rights-to-OraPro-oral-vaccine-platform-technology-for-COVID-19.html
-
Rheumatologen warnen vor Fehlinformation über Coronaimpfung
(Hinzugefügt: 13.01.2021 um 08:08 Uhr)
https://www.aerzteblatt.de/nachrichten/120079/Rheumatologen-warnen-vor-Fehlinformation-ueber-Coronaimpfung
-
Inhaling away the virus: Is the next generation of COVID vaccines on their way?
(Hinzugefügt: 12.01.2021 um 07:59 Uhr)
https://codagenix.com/news/
-
Kuba plant Phase-3-Studie seines Coronaimpfstoffs im Iran
(Hinzugefügt: 12.01.2021 um 07:55 Uhr)
https://www.aerzteblatt.de/nachrichten/120022/Kuba-plant-Phase-3-Studie-seines-Coronaimpfstoffs-im-Iran
-
Stanford developing single-dose nanoparticle vaccine for COVID-19
(Hinzugefügt: 10.01.2021 um 19:46 Uhr)
https://medicalxpress.com/news/2021-01-stanford-single-dose-nanoparticle-vaccine-covid-.html
-
A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice
(Hinzugefügt: 10.01.2021 um 19:32 Uhr)
https://pubs.acs.org/doi/10.1021/acscentsci.0c01405
-
COVID-19-Impfstoffe (Paul- Ehrlich- Institut)
(Hinzugefügt: 10.01.2021 um 09:27 Uhr)
https://www.pei.de/DE/arzneimittel/impfstoffe/covid-19/covid-19-node.html
-
Coronaimpfstoffe: Viele Antworten auf wichtige Fragen bereits aufbereitet
(Hinzugefügt: 10.01.2021 um 09:24 Uhr)
https://www.aerzteblatt.de/nachrichten/119910/Coronaimpfstoffe-Viele-Antworten-auf-wichtige-Fragen-bereits-aufbereitet
-
Impfstoffentwicklung am UKE verzögert sich, Immunantwort unerwartet gering
(Hinzugefügt: 09.01.2021 um 10:26 Uhr)
https://www.aerzteblatt.de/nachrichten/119985/Impfstoffentwicklung-am-UKE-verzoegert-sich-Immunantwort-unerwartet-gering
-
COVID-19: Single vaccine dose leads to 'greater risk' from new coronavirus variants, South African experts warn
(Hinzugefügt: 07.01.2021 um 05:17 Uhr)
https://news.sky.com/story/covid-19-single-vaccine-dose-leads-to-greater-risk-from-new-coronavirus-variants-south-african-experts-warn-12180837
-
Stanford Scientists Are Creating Single-Dose Nanoparticle COVID-19 Vaccine
(Hinzugefügt: 06.01.2021 um 08:50 Uhr)
https://interestingengineering.com/stanford-scientists-are-creating-single-dose-nanoparticle-covid-19-vaccine
-
New ReiThera vaccine safe, response peak at 4 wks
(Hinzugefügt: 05.01.2021 um 17:47 Uhr)
https://www.lagazzettadelmezzogiorno.it/news/english/1271075/new-reithera-vaccine-safe-response-peak-at-4-wks.html
-
New ReiThera vaccine safe, response peak at 4 wks
(Hinzugefügt: 05.01.2021 um 17:47 Uhr)
https://www.lagazzettadelmezzogiorno.it/news/english/1271075/new-reithera-vaccine-safe-response-peak-at-4-wks.html
-
A guide to vaccinology: from basic principles to new developments
(Hinzugefügt: 05.01.2021 um 16:51 Uhr)
https://www.nature.com/articles/s41577-020-00479-7
-
Variants and Vaccines
(Hinzugefügt: 05.01.2021 um 07:56 Uhr)
https://blogs.sciencemag.org/pipeline/archives/2021/01/04/variants-and-vaccines
-
#DoNotSqueezeMyArm: Doctor Sounds Alarm on How to Properly Inject COVID-19 Vaccine
(Hinzugefügt: 03.01.2021 um 09:37 Uhr)
https://www.nbcmiami.com/news/donotsqueezemyarm-doctor-sounds-alarm-on-how-to-properly-inject-covid-19-vaccine/2353866/
-
Monitor for COVID-19 vaccine resistance evolution during clinical trials
(Hinzugefügt: 02.01.2021 um 09:08 Uhr)
https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3001000
-
Commentary: Pharmaceutical firms saved the world with COVID-19 vaccine in record time. But credit goes to others too
(Hinzugefügt: 01.01.2021 um 19:12 Uhr)
https://www.channelnewsasia.com/news/commentary/covid-19-coronavirus-vaccine-record-time-pharmaceuticals-safe-13870176
-
Vaccine Roundup, Late December
(Hinzugefügt: 31.12.2020 um 11:19 Uhr)
https://blogs.sciencemag.org/pipeline/archives/2020/12/30/vaccine-roundup-late-december
-
Maintaining Safety with SARS-CoV-2 Vaccines
(Hinzugefügt: 31.12.2020 um 11:19 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMra2035343
-
Messengers of hope
(Hinzugefügt: 30.12.2020 um 08:04 Uhr)
https://www.nature.com/articles/s41587-020-00807-1
-
Arcturus Therapeutics Received Approval from Singapore Health Sciences Authority to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate and Provides New and Updated Clinical and Preclinical Data
(Hinzugefügt: 30.12.2020 um 07:54 Uhr)
https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-received-approval-singapore-health
-
BMG stellt Aufklärungs- und Informationsmaterialien zur Coronaimpfung bereit
(Hinzugefügt: 28.12.2020 um 19:07 Uhr)
https://www.aerzteblatt.de/nachrichten/119709/BMG-stellt-Aufklaerungs-und-Informationsmaterialien-zur-Coronaimpfung-bereit
-
More Than 4.4 Million Shots Given: Covid-19 Vaccine Tracker The U.S. has administered 1.94 million doses, according to the CDC
(Hinzugefügt: 28.12.2020 um 08:41 Uhr)
https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/
-
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial
(Hinzugefügt: 25.12.2020 um 08:11 Uhr)
https://www.sciencedirect.com/science/article/pii/S2589537020304338
-
Older Adults’ Perspectives on a COVID-19 Vaccine
(Hinzugefügt: 24.12.2020 um 08:49 Uhr)
https://jamanetwork.com/channels/health-forum/fullarticle/2774598
-
Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report
(Hinzugefügt: 23.12.2020 um 20:29 Uhr)
https://www.medrxiv.org/content/10.1101/2020.12.21.20248643v1
-
Neue Impfstoffe: So werden Nebenwirkungen überwacht
(Hinzugefügt: 23.12.2020 um 08:33 Uhr)
https://www.aerzteblatt.de/nachrichten/119646/Neue-Impfstoffe-So-werden-Nebenwirkungen-ueberwacht
-
COVID-19 Vaccine approval map
(Hinzugefügt: 21.12.2020 um 17:18 Uhr)
https://sites.google.com/view/covidvaxmap
-
EMA recommends first COVID-19 vaccine for authorisation in the EU
(Hinzugefügt: 21.12.2020 um 17:16 Uhr)
https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu
-
Why Two Vaccines Passed the Finishing Line In a Year and Others Didn’t, and a Month 12 Roundup
(Hinzugefügt: 21.12.2020 um 10:54 Uhr)
https://absolutelymaybe.plos.org/2020/12/20/why-two-vaccines-passed-the-finishing-line-in-a-year-and-others-didnt-and-a-month-12-roundup/
-
Viral targets for vaccines against COVID-19
(Hinzugefügt: 21.12.2020 um 10:53 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747004/
-
Sterilizing immunity against SARS-CoV-2 in hamsters conferred by a novel recombinant subunit vaccine
(Hinzugefügt: 21.12.2020 um 10:48 Uhr)
https://www.biorxiv.org/content/10.1101/2020.12.18.423552v1
-
Coronaimpfstoff: Diese Nachteile birgt eine Notfallzulassung
(Hinzugefügt: 20.12.2020 um 09:31 Uhr)
https://www.aerzteblatt.de/nachrichten/119502/Coronaimpfstoff-Diese-Nachteile-birgt-eine-Notfallzulassung
-
Covid-19 vaccines: delivering protective immunity
(Hinzugefügt: 19.12.2020 um 09:27 Uhr)
https://www.bmj.com/content/371/bmj.m4838
-
Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines
(Hinzugefügt: 19.12.2020 um 09:14 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2774383
-
COVID-19 vaccines: the pandemic will not end overnight
(Hinzugefügt: 19.12.2020 um 09:00 Uhr)
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(20)30226-3/fulltext
-
Antibody-Dependent Enhancement
(Hinzugefügt: 18.12.2020 um 21:42 Uhr)
https://blogs.sciencemag.org/pipeline/archives/2020/12/18/antibody-dependent-enhancement
-
De Bleeker legt grote prijsverschillen tussen vaccins bloot
(Hinzugefügt: 18.12.2020 um 10:43 Uhr)
https://www.tijd.be/politiek-economie/belgie/algemeen/de-bleeker-legt-grote-prijsverschillen-tussen-vaccins-bloot/10272703.html
-
A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge
(Hinzugefügt: 18.12.2020 um 10:28 Uhr)
https://www.nature.com/articles/s41467-020-20228-7
-
COVID-19 vaccine and Guillain-Barré syndrome: let’s not leap to associations
(Hinzugefügt: 17.12.2020 um 08:34 Uhr)
https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awaa444/6031904
-
Pandemic Vaccines: How Are We Going to Be Better Prepared Next Time?
(Hinzugefügt: 16.12.2020 um 19:04 Uhr)
https://www.cell.com/med/fulltext/S2666-6340(20)30027-1
-
Safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152: a phase 1, double-blind, randomised control trial
(Hinzugefügt: 16.12.2020 um 19:01 Uhr)
https://www.medrxiv.org/content/10.1101/2020.12.11.20210419v1
-
Valneva Initiates Phase 1/2 Clinical Study of Inactivated, Adjuvanted COVID-19 Vaccine Candidate
(Hinzugefügt: 16.12.2020 um 19:01 Uhr)
https://valneva.com/press-release/valneva-initiates-phase-1-2-clinical-study-of-inactivated-adjuvanted-covid-19-vaccine-candidate/
-
Entwicklung von Coronaimpfstoff in Australien gestoppt
(Hinzugefügt: 12.12.2020 um 08:49 Uhr)
https://www.aerzteblatt.de/nachrichten/119284/Entwicklung-von-Coronaimpfstoff-in-Australien-gestoppt
-
A single dose, BCG-adjuvanted SARS-CoV-2 vaccine induces Th1-polarized immunity and high-titre neutralizing antibodies in mice
(Hinzugefügt: 11.12.2020 um 22:44 Uhr)
https://www.biorxiv.org/content/10.1101/2020.12.10.419044v1
-
A Wider Variety of Vaccine Platforms Report
(Hinzugefügt: 11.12.2020 um 22:42 Uhr)
https://blogs.sciencemag.org/pipeline/archives/2020/12/11/a-wider-variety-of-vaccine-platforms-report
-
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly
(Hinzugefügt: 11.12.2020 um 22:34 Uhr)
https://www.sanofi.com/en/media-room/press-releases/2020/2020-12-11-07-00-00
-
Update on The University of Queensland COVID-19 vaccine
(Hinzugefügt: 11.12.2020 um 22:32 Uhr)
https://www.csl.com/news/2020/20201211-update-on-the-university-of-queensland-covid-19-vaccine
-
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly
(Hinzugefügt: 11.12.2020 um 08:10 Uhr)
https://www.finanzen.net/nachricht/aktien/sanofi-and-gsk-announce-a-delay-in-their-adjuvanted-recombinant-protein-based-covid-19-vaccine-program-to-improve-immune-response-in-the-elderly-9603794
-
CEPI and SK bioscience extend collaboration to develop ‘next generation’ COVID-19 vaccine
(Hinzugefügt: 11.12.2020 um 08:09 Uhr)
https://cepi.net/news_cepi/cepi-and-sk-bioscience-to-develop-next-generation-covid-19-vaccine/
-
A Nursing Researcher’s Experience in a COVID-19 Vaccine Trial
(Hinzugefügt: 09.12.2020 um 18:44 Uhr)
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2773790
-
Oxford-AstraZeneca Vaccine Effective But Questions Remain for Elderly
(Hinzugefügt: 09.12.2020 um 00:28 Uhr)
https://www.bloomberg.com/news/articles/2020-12-08/astra-vaccine-is-effective-but-leaves-questions-in-older-ages
-
Provisional guidance subject to MHRA approval of vaccine supply
(Hinzugefügt: 09.12.2020 um 00:18 Uhr)
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/941450/Greenbook_chapter_14a_v2.pdf
-
FDA PFIZER-BIONTECH COVID-19 VACCINE (BNT162, PF-07302048)
(Hinzugefügt: 09.12.2020 um 00:18 Uhr)
https://www.fda.gov/media/144246/download
-
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
(Hinzugefügt: 09.12.2020 um 00:13 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext
-
Curevac peilt Zulassung in der EU und in Lateinamerika an
(Hinzugefügt: 08.12.2020 um 09:03 Uhr)
https://www.aerzteblatt.de/nachrichten/119072/Curevac-peilt-Zulassung-in-der-EU-und-in-Lateinamerika-an
-
A first-in-human evaluation of the safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19 in healthy adults; a phase 1, randomised, double-blind, placebo-controlled trial
(Hinzugefügt: 07.12.2020 um 07:50 Uhr)
https://www.medrxiv.org/content/10.1101/2020.12.03.20243709v1
-
Sputnik V: Russia rolls out its COVID-19 vaccination programme
(Hinzugefügt: 06.12.2020 um 17:07 Uhr)
https://www.euronews.com/2020/12/05/sputnik-v-russia-rolls-out-its-covid-19-vaccination-programme
-
Johns Hopkins Researcher Calls out FDA, Says His Team Could Approve COVID Vaccine in an Hour
(Hinzugefügt: 06.12.2020 um 17:04 Uhr)
https://www.newsweek.com/johns-hopkins-researcher-calls-out-fda-says-his-team-could-approve-covid-vaccine-hour-1552567
-
COVID-19 vaccine trial ethics once we have efficacious vaccines
(Hinzugefügt: 05.12.2020 um 08:24 Uhr)
https://science.sciencemag.org/content/early/2020/12/02/science.abf5084.full
-
Moderna Provides Updates on the Clinical Development and Production of Its COVID-19 Vaccine Candidate
(Hinzugefügt: 04.12.2020 um 09:22 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-updates-clinical-development-and-production-its/
-
Moderna Provides Updates on the Clinical Development and Production of Its COVID-19 Vaccine Candidate
(Hinzugefügt: 04.12.2020 um 09:22 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-updates-clinical-development-and-production-its/
-
Fortune or foresight? AstraZeneca and Oxford's stories clash on COVID-19 vaccine
(Hinzugefügt: 04.12.2020 um 09:22 Uhr)
https://www.reuters.com/article/health-coronavirus-astrazeneca-insight-i-idUSKBN28D2AM
-
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
(Hinzugefügt: 04.12.2020 um 09:19 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2032195
-
Coronaimpfstoff: Was bedeutet „90 Prozent wirksam“?
(Hinzugefügt: 03.12.2020 um 18:25 Uhr)
https://www.aerzteblatt.de/nachrichten/118956/Coronaimpfstoff-Was-bedeutet-90-Prozent-wirksam
-
Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and their Augmentation by Compact Peptide Sets
(Hinzugefügt: 03.12.2020 um 18:24 Uhr)
https://www.biorxiv.org/content/10.1101/2020.08.04.200691v2
-
Covid-19 Vaccine Efficacy | Could It Be Due to Chance?
(Hinzugefügt: 03.12.2020 um 18:21 Uhr)
http://jeffgalak.com/datademystified/index.php/2020/12/03/covid-19-vaccine-efficacy-could-it-be-due-to-chance/
-
ab min 10: Press Conference Biontech
(Hinzugefügt: 03.12.2020 um 18:19 Uhr)
https://player.admiralcloud.com/?v=5c1fecc2-f902-4886-b87b-5bcac76b7c2d
-
Corona-Überraschung: Pharmafirma Janssen beantragt schrittweise Zulassung für Impfstoff in der EU
(Hinzugefügt: 03.12.2020 um 12:24 Uhr)
https://www.businessinsider.de/wissenschaft/gesundheit/janssen-beantragt-schrittweise-zulassung-fuer-corona-impfstoff-in-der-eu/?utm_source=rss&utm_medium=rss&utm_campaign=janssen-beantragt-schrittweise-zulassung-fuer-corona-impfstoff-in-der-eu
-
A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine
(Hinzugefügt: 02.12.2020 um 23:20 Uhr)
https://www.pnas.org/content/early/2020/11/25/2014468117
-
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
(Hinzugefügt: 02.12.2020 um 23:14 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2028436
-
Placebo-Controlled Trials of Covid-19 Vaccines — Why We Still Need Them
(Hinzugefügt: 02.12.2020 um 23:14 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMp2033538
-
Großbritannien erteilt Notfallzulassung für Coronaimpfstoff von Biontech
(Hinzugefügt: 02.12.2020 um 22:56 Uhr)
https://www.aerzteblatt.de/nachrichten/118923/Grossbritannien-erteilt-Notfallzulassung-fuer-Coronaimpfstoff-von-Biontech
-
Volunteer’s doc blames SII vaccine for neuro disorder
(Hinzugefügt: 02.12.2020 um 22:16 Uhr)
https://www.livemint.com/science/health/volunteer-s-doc-blames-sii-vaccine-for-neuro-disorder-11606880532345.html
-
Taking Two Different Vaccines?
(Hinzugefügt: 02.12.2020 um 22:08 Uhr)
https://blogs.sciencemag.org/pipeline/archives/2020/12/02/taking-two-different-vaccines
-
Johnson & Johnson Announces Initiation of Rolling Submission for its Single-dose Janssen COVID-19 Vaccine Candidate with the European Medicines Agency
(Hinzugefügt: 02.12.2020 um 22:04 Uhr)
https://www.jnj.com/our-company/johnson-johnson-announces-initiation-of-rolling-submission-for-its-single-dose-janssen-covid-19-vaccine-candidate-with-the-european-medicines-agency
-
US scientists developing nasal spray to prevent Covid-19
(Hinzugefügt: 02.12.2020 um 10:21 Uhr)
https://www.msn.com/en-us/news/world/us-scientists-developing-nasal-spray-to-prevent-covid-19/ar-BB1bxiLC
-
UK authorises Pfizer/BioNTech COVID-19 vaccine
(Hinzugefügt: 02.12.2020 um 10:17 Uhr)
https://www.gov.uk/government/news/uk-authorises-pfizer-biontech-covid-19-vaccine
-
The differences between the Pfizer, Moderna and Oxford coronavirus vaccines: what we know so far
(Hinzugefügt: 02.12.2020 um 10:00 Uhr)
https://english.elpais.com/science_tech/2020-12-01/the-differences-between-the-pfizer-moderna-and-oxford-coronavirus-vaccines-what-we-know-so-far.html
-
What you need to know about the AstraZeneca, Moderna and Pfizer vaccines
(Hinzugefügt: 02.12.2020 um 09:59 Uhr)
https://www.washingtonpost.com/health/2020/11/17/covid-vaccines-what-you-need-to-know/?arc404=true
-
Design of a multi-epitope vaccine against SARS-CoV-2 using immunoinformatics approach
(Hinzugefügt: 02.12.2020 um 09:47 Uhr)
https://www.sciencedirect.com/science/article/pii/S0141813020338708
-
A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
(Hinzugefügt: 02.12.2020 um 09:46 Uhr)
https://www.nature.com/articles/s41586-020-3035-9
-
Krebstherapie als Vorbild Uni Tübingen entwickelt eigenen Impfstoff
(Hinzugefügt: 02.12.2020 um 09:40 Uhr)
https://www.n-tv.de/wissen/Uni-Tuebingen-entwickelt-eigenen-Impfstoff-article22207798.html
-
THE COST OF ONE DOSE OF THE SPUTNIK V VACCINE WILL BE LESS THAN $10 FOR INTERNATIONAL MARKETS
(Hinzugefügt: 01.12.2020 um 08:43 Uhr)
https://sputnikvaccine.com/newsroom/pressreleases/the-cost-of-one-dose-will-be-less-than-10-for-international-markets/
-
Here's a look at how the different coronavirus vaccines work
(Hinzugefügt: 01.12.2020 um 08:39 Uhr)
https://edition.cnn.com/2020/11/24/health/covid-vaccines-design-explained/index.html
-
Behind the use of mRNA vaccine technology in COVID-19
(Hinzugefügt: 01.12.2020 um 08:33 Uhr)
https://www.atpresentworld.com/2020/11/behind-use-of-mrna-vaccine-technology.html
-
Covid-19 vaccines: where are the data?
(Hinzugefügt: 01.12.2020 um 08:07 Uhr)
https://blogs.bmj.com/bmj/2020/11/27/covid-19-vaccines-where-are-the-data/
-
Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization
(Hinzugefügt: 01.12.2020 um 08:04 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study/
-
Novavax Announces COVID-19 Vaccine Clinical Development Progress
(Hinzugefügt: 01.12.2020 um 08:03 Uhr)
https://ir.novavax.com/news-releases/news-release-details/novavax-announces-covid-19-vaccine-clinical-development-progress
-
‘Absolutely remarkable’: No one who got Moderna’s vaccine in trial developed severe COVID-19
(Hinzugefügt: 01.12.2020 um 08:01 Uhr)
https://www.sciencemag.org/news/2020/11/absolutely-remarkable-no-one-who-got-modernas-vaccine-trial-developed-severe-covid-19
-
Toward superhuman SARS-CoV-2 immunity?
(Hinzugefügt: 01.12.2020 um 08:00 Uhr)
https://www.nature.com/articles/s41591-020-01180-x
-
Canadian company says its COVID-19 vaccine spurred 'promising antibody response' in Phase 1 of trials
(Hinzugefügt: 29.11.2020 um 13:11 Uhr)
https://www.ctvnews.ca/health/coronavirus/canadian-company-says-its-covid-19-vaccine-spurred-promising-antibody-response-in-phase-1-of-trials-1.5182087
-
REPORT Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate View ORCID Profile
(Hinzugefügt: 29.11.2020 um 13:10 Uhr)
https://science.sciencemag.org/content/370/6520/1089.full
-
Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates
(Hinzugefügt: 28.11.2020 um 09:47 Uhr)
https://www.nature.com/articles/s41591-020-01172-x.epdf?sharing_token=ktvzP4CCPBr3KQkRrNlL1NRgN0jAjWel9jnR3ZoTv0Nebsa_D-Xo28crd261hR7eZAyZSqrXZjzpPvuMc4JkOhetCKPAjivPBP0CQFZjianj2XDwP12PfwaK_k9SjyF_003MK_L56Bu4IRBcdm6gc3WiXU35wbyWQlemWlskiME%3D
-
Oxford/AstraZeneca COVID-19 vaccine: MHRA statement confirming letter received
(Hinzugefügt: 27.11.2020 um 21:47 Uhr)
https://www.gov.uk/government/news/oxfordastrazeneca-covid-19-vaccine-mhra-statement-confirming-letter-received
-
NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge
(Hinzugefügt: 27.11.2020 um 11:15 Uhr)
https://www.sciencedirect.com/science/article/pii/S0264410X20313736
-
Public needs to prep for vaccine side effects
(Hinzugefügt: 27.11.2020 um 11:13 Uhr)
https://science.sciencemag.org/content/370/6520/1022.full
-
Impfstoffe: Warum Sputnik V eine höhere Effektivität gegen SARS-CoV-2 erzielen könnte als AZD1222
(Hinzugefügt: 27.11.2020 um 11:02 Uhr)
https://www.aerzteblatt.de/nachrichten/118731/Impfstoffe-Warum-Sputnik-V-eine-hoehere-Effektivitaet-gegen-SARS-CoV-2-erzielen-koennte-als-AZD1222
-
Impfstoffe: Warum Sputnik V eine höhere Effektivität gegen SARS-CoV-2 erzielen könnte als AZD1222
(Hinzugefügt: 27.11.2020 um 11:02 Uhr)
https://www.aerzteblatt.de/nachrichten/118731/Impfstoffe-Warum-Sputnik-V-eine-hoehere-Effektivitaet-gegen-SARS-CoV-2-erzielen-koennte-als-AZD1222
-
Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses
(Hinzugefügt: 27.11.2020 um 10:46 Uhr)
https://www.cell.com/immunity/fulltext/S1074-7613(20)30502-1
-
Covid-19: What do we know about the late stage vaccine candidates?
(Hinzugefügt: 26.11.2020 um 09:05 Uhr)
https://www.bmj.com/content/371/bmj.m4576
-
Here's a look at how the different coronavirus vaccines work
(Hinzugefügt: 26.11.2020 um 09:03 Uhr)
https://edition.cnn.com/2020/11/24/health/covid-vaccines-design-explained/index.html
-
Astra Vaccine’s 90% Efficacy in Covid Came in Younger Group
(Hinzugefügt: 26.11.2020 um 08:52 Uhr)
https://www.bloomberg.com/news/articles/2020-11-24/astra-vaccine-s-90-efficacy-in-covid-came-in-younger-population
-
Biontech-Manager erwartet hohe Produktionskapazitäten für Coronaimpfstoff
(Hinzugefügt: 26.11.2020 um 08:32 Uhr)
https://www.aerzteblatt.de/nachrichten/118732/Biontech-Manager-erwartet-hohe-Produktionskapazitaeten-fuer-Coronaimpfstoff
-
Impfstoffe: Warum Sputnik V eine höhere Effektivität gegen SARS-CoV-2 erzielen könnte als AZD1222
(Hinzugefügt: 26.11.2020 um 08:30 Uhr)
https://www.aerzteblatt.de/nachrichten/118731/Impfstoffe-Warum-Sputnik-V-eine-hoehere-Effektivitaet-gegen-SARS-CoV-2-erzielen-koennte-als-AZD1222
-
With more data on its COVID-19 vaccine, Russian institute offers new evidence of success
(Hinzugefügt: 25.11.2020 um 09:23 Uhr)
https://www.sciencemag.org/news/2020/11/more-data-its-covid-19-vaccine-russia-institute-offers-new-evidence-success
-
SECOND INTERIM ANALYSIS OF CLINICAL TRIAL DATA SHOWED A 91.4% EFFICACY FOR THE SPUTNIK V VACCINE
(Hinzugefügt: 24.11.2020 um 20:45 Uhr)
https://sputnikvaccine.com/newsroom/pressreleases/second-interim-analysis-of-clinical-trial-data-showed-a-91-4-efficacy-for-the-sputnik-v-vaccine-on-d/
-
Astra Zeneca Another COVID-19 vaccine success? Candidate may prevent further coronavirus transmission, too
(Hinzugefügt: 24.11.2020 um 20:34 Uhr)
https://www.sciencemag.org/news/2020/11/another-covid-19-vaccine-success-candidate-may-prevent-further-coronavirus-transmission
-
Why Oxford’s positive COVID vaccine results are puzzling scientists
(Hinzugefügt: 24.11.2020 um 10:26 Uhr)
https://www.nature.com/articles/d41586-020-03326-w
-
Why emergency COVID-vaccine approvals pose a dilemma for scientists
(Hinzugefügt: 24.11.2020 um 10:26 Uhr)
https://www.nature.com/articles/d41586-020-03219-y
-
Britischer Impfstoff erzielt in höherer Dosis schwächere Wirkung
(Hinzugefügt: 24.11.2020 um 09:32 Uhr)
https://www.aerzteblatt.de/nachrichten/118646/COVID-19-Britischer-Impfstoff-erzielt-in-hoeherer-Dosis-schwaechere-Wirkung
-
Brazil has enough infection data to analyze Sinovac's COVID-19 vaccine - officials
(Hinzugefügt: 24.11.2020 um 09:30 Uhr)
https://www.reuters.com/article/us-health-coronavirus-brazil-sinovac-idUSKBN28327C
-
Brazil has enough infection data to analyze Sinovac's COVID-19 vaccine - officials
(Hinzugefügt: 24.11.2020 um 09:30 Uhr)
https://www.reuters.com/article/us-health-coronavirus-brazil-sinovac-idUSKBN28327C
-
Impfstoff-Studie gestoppt: Rückschlag für China
(Hinzugefügt: 24.11.2020 um 09:29 Uhr)
https://www.fr.de/politik/impfstoff-studie-gestoppt-rueckschlag-fuer-china-90096236.html
-
Dosing error turns into lucky punch for AstraZeneca and Oxford
(Hinzugefügt: 24.11.2020 um 09:26 Uhr)
https://www.reuters.com/article/us-health-coronavirus-astrazeneca-dosing-idUSKBN28327Q
-
Why emergency COVID-vaccine approvals pose a dilemma for scientists
(Hinzugefügt: 24.11.2020 um 09:25 Uhr)
https://www.nature.com/articles/d41586-020-03219-y
-
Why Oxford’s positive COVID vaccine results are puzzling scientists
(Hinzugefügt: 24.11.2020 um 09:23 Uhr)
https://www.nature.com/articles/d41586-020-03326-w
-
AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19
(Hinzugefügt: 24.11.2020 um 09:19 Uhr)
https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html
-
Oxford/AZ Vaccine Efficacy Data
(Hinzugefügt: 24.11.2020 um 09:16 Uhr)
https://blogs.sciencemag.org/pipeline/archives/2020/11/23/oxford-az-vaccine-efficacy-data
-
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
(Hinzugefügt: 23.11.2020 um 15:41 Uhr)
https://www.nejm.org/doi/10.1056/NEJMoa2027906?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
-
AstraZeneca-Impfstoff „verblüffend“ - niedrige Dosis wirkt besser als hohe
(Hinzugefügt: 23.11.2020 um 15:14 Uhr)
https://www.welt.de/politik/ausland/article220777642/AstraZeneca-Impfstoff-verblueffend-niedrige-Dosis-wirkt-besser-als-hohe.html
-
CORONA-IMPFSTOFF VON CUREVAC Kühlschranklagerung genügt
(Hinzugefügt: 23.11.2020 um 10:45 Uhr)
https://www.deutsche-apotheker-zeitung.de/news/artikel/2020/11/12/kuehlschranklagerung-genuegt
-
AstraZeneca COVID-19 vaccine AZD1222
(Hinzugefügt: 23.11.2020 um 07:49 Uhr)
https://www.astrazeneca.com/media-centre/articles/2020/covid-19-vaccine-azd1222-is-better-tolerated-in-older-adults-than-younger-adults-with-similar-immune-responses-across-all-age-groups.html
-
FDA Emergency Use Authorization for Vaccines Explained
(Hinzugefügt: 22.11.2020 um 21:19 Uhr)
https://www.fda.gov/vaccines-blood-biologics/vaccines/emergency-use-authorization-vaccines-explained
-
Pfizer COVID-19 vaccine could get UK approval this week: Telegraph
(Hinzugefügt: 22.11.2020 um 21:17 Uhr)
https://in.reuters.com/article/us-health-coronavirus-vaccines-pfizer-br-idINKBN2820QU
-
We can’t defeat COVID-19 without vaccinating children
(Hinzugefügt: 22.11.2020 um 09:58 Uhr)
https://www.aamc.org/news-insights/we-can-t-defeat-covid-19-without-vaccinating-children-there-arent-even-any-kids-clinical-trials-yet
-
»Sputnik V« Was steckt hinter dem russischen Impfstoff?
(Hinzugefügt: 22.11.2020 um 09:38 Uhr)
https://www.pharmazeutische-zeitung.de/was-steckt-hinter-dem-russischen-impfstoff-119526/
-
Sputnik V soll hoch wirksam sein
(Hinzugefügt: 22.11.2020 um 09:38 Uhr)
https://www.aerzteblatt.de/nachrichten/118283/Sputnik-V-soll-hoch-wirksam-sein
-
FDA Announces Advisory Committee Meeting to Discuss COVID-19 Vaccine Candidate
(Hinzugefügt: 22.11.2020 um 09:31 Uhr)
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-announces-advisory-committee-meeting-discuss-covid-19-vaccine
-
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
(Hinzugefügt: 20.11.2020 um 16:02 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32466-1/fulltext
-
Warum mRNA-Impfstoffe nicht das Erbgut verändern
(Hinzugefügt: 20.11.2020 um 16:00 Uhr)
https://www.pharmazeutische-zeitung.de/warum-mrna-impfstoffe-nicht-das-erbgut-veraendern-121972/
-
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine
(Hinzugefügt: 20.11.2020 um 08:59 Uhr)
https://www.sciencedirect.com/science/article/pii/S0140673620324661
-
Coronavirus: 1 million Chinese injected with Sinopharm vaccine under emergency use scheme
(Hinzugefügt: 20.11.2020 um 08:50 Uhr)
https://www.scmp.com/news/china/society/article/3110519/china-sinopharms-coronavirus-vaccine-taken-about-1-million
-
More Vaccine Data, in Advance of More Efficacy
(Hinzugefügt: 20.11.2020 um 08:46 Uhr)
https://blogs.sciencemag.org/pipeline/archives/2020/11/19/more-vaccine-data-in-advance-of-more-efficacy
-
COVID-19 vaccines
(Hinzugefügt: 20.11.2020 um 08:32 Uhr)
https://www.biocentury.com/article/632064
-
SARS-CoV-2: Britischer Impfstoff erzielt in Phase-2/3-Studie auch bei (gesunden) Senioren eine hohe Immunität
(Hinzugefügt: 20.11.2020 um 08:16 Uhr)
https://www.aerzteblatt.de/nachrichten/118531/SARS-CoV-2-Britischer-Impfstoff-erzielt-in-Phase-2-3-Studie-auch-bei-(gesunden)-Senioren-eine-hohe-Immunitaet
-
Sinovac's COVID-19 vaccine induces quick immune response: study
(Hinzugefügt: 19.11.2020 um 08:11 Uhr)
https://www.reuters.com/article/us-health-coronavirus-sinovac-idUSKBN27X354
-
Coronaimpfstoff: Pfizer und Biontech melden 95 % Wirksamkeit
(Hinzugefügt: 19.11.2020 um 08:08 Uhr)
https://www.aerzteblatt.de/nachrichten/118490/Coronaimpfstoff-Pfizer-und-Biontech-melden-95-Wirksamkeit
-
ChAdOx1 nCoV-19 vaccine
(Hinzugefügt: 19.11.2020 um 07:59 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32466-1/fulltext
-
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
(Hinzugefügt: 18.11.2020 um 09:42 Uhr)
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30843-4/fulltext
-
Ensuring vaccine safety
(Hinzugefügt: 18.11.2020 um 09:37 Uhr)
https://science.sciencemag.org/content/early/2020/11/16/science.abf0357.full
-
European Medicines Agency Begins Rolling Review of Moderna’s mRNA Vaccine Candidate
(Hinzugefügt: 18.11.2020 um 09:10 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/european-medicines-agency-begins-rolling-review-modernas-mrna/
-
Moderna’s Vaccine Efficacy Readout
(Hinzugefügt: 17.11.2020 um 08:56 Uhr)
https://blogs.sciencemag.org/pipeline/archives/2020/11/16/modernas-vaccine-efficacy-readout
-
Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine
(Hinzugefügt: 17.11.2020 um 08:56 Uhr)
https://www.nih.gov/news-events/news-releases/promising-interim-results-clinical-trial-nih-moderna-covid-19-vaccine
-
Moderna’s Vaccine Efficacy Readout
(Hinzugefügt: 17.11.2020 um 08:56 Uhr)
https://blogs.sciencemag.org/pipeline/archives/2020/11/16/modernas-vaccine-efficacy-readout
-
Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine
(Hinzugefügt: 17.11.2020 um 08:56 Uhr)
https://www.nih.gov/news-events/news-releases/promising-interim-results-clinical-trial-nih-moderna-covid-19-vaccine
-
Johnson & Johnson Initiates Second Global Phase 3 Clinical Trial
(Hinzugefügt: 17.11.2020 um 08:49 Uhr)
https://www.jnj.com/johnson-johnson-initiates-second-global-phase-3-clinical-trial-of-its-janssen-covid-19-vaccine-candidate
-
Sanofi-Impfstoffkandidat kann bei Kühlschranktemperatur gelagert werden
(Hinzugefügt: 16.11.2020 um 20:56 Uhr)
https://www.aerzteblatt.de/nachrichten/118386/Sanofi-Impfstoffkandidat-kann-bei-Kuehlschranktemperatur-gelagert-werden
-
Impfstoff von Moderna erreicht Schutzwirkung von 94,5 %
(Hinzugefügt: 16.11.2020 um 20:54 Uhr)
https://www.aerzteblatt.de/nachrichten/118405/SARS-CoV-2-Impfstoff-von-Moderna-erreicht-Schutzwirkung-von-94-5
-
Curevac: Impfstoffkandidat bei Kühlschranktemperatur Monate haltbar
(Hinzugefügt: 13.11.2020 um 08:31 Uhr)
https://www.aerzteblatt.de/nachrichten/118324/Curevac-Impfstoffkandidat-bei-Kuehlschranktemperatur-Monate-haltbar
-
Moderna Case Accrual (mRNA-1273)
(Hinzugefügt: 12.11.2020 um 08:06 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-has-completed-case-accrual-first-planned-interim/
-
Russia announces positive COVID-vaccine results from controversial trial
(Hinzugefügt: 11.11.2020 um 20:18 Uhr)
https://www.nature.com/articles/d41586-020-03209-0
-
Biontech: Grünes Licht aus Brüssel, Bundesregierung will zur Not nachverhandeln
(Hinzugefügt: 11.11.2020 um 20:13 Uhr)
https://www.aerzteblatt.de/nachrichten/118252/Coronaimpfstoff-von-Biontech-Gruenes-Licht-aus-Bruessel-Bundesregierung-will-zur-Not-nachverhandeln
-
Sputnik V soll hoch wirksam sein
(Hinzugefügt: 11.11.2020 um 20:10 Uhr)
https://www.aerzteblatt.de/nachrichten/118283/Sputnik-V-soll-hoch-wirksam-sein
-
Belgian hospital resumes Johnson & Johnson coronavirus vaccine trials
(Hinzugefügt: 11.11.2020 um 20:01 Uhr)
https://www.brusselstimes.com/news/belgium-all-news/140219/belgian-hospital-resumes-johnson-johnson-coronavirus-vaccine-trials-uz-gent-ghent-cevac-phase-3-unexplained-illness-curevac/
-
Brazil resumes trials of Chinese coronavirus vaccine
(Hinzugefügt: 11.11.2020 um 19:59 Uhr)
https://www.aa.com.tr/en/americas/brazil-resumes-trials-of-chinese-coronavirus-vaccine/2040532
-
China's Sinopharm says data 'better than expected" from unit's COVID-19 vaccine trials
(Hinzugefügt: 11.11.2020 um 19:58 Uhr)
https://www.reuters.com/article/health-coronavirus-vaccine-china-idUSKBN27R1Q1
-
Siberian Healthcare Workers Who Were Given Sputnik V Vaccine Get COVID
(Hinzugefügt: 11.11.2020 um 19:55 Uhr)
https://www.newsweek.com/russia-vaccine-covid-healthcare-workers-siberia-1546606
-
Protective efficacy of a SARS-CoV-2 DNA Vaccine in wild-type and immunosuppressed Syrian hamsters
(Hinzugefügt: 11.11.2020 um 19:49 Uhr)
https://www.biorxiv.org/content/10.1101/2020.11.10.376905v1
-
SPUTNIK V VACCINE
(Hinzugefügt: 11.11.2020 um 19:44 Uhr)
https://sputnikvaccine.com/newsroom/pressreleases/the-first-interim-data-analysis-of-the-sputnik-v-vaccine-against-covid-19-phase-iii-clinical-trials-/
-
Impfstoff von Curevac erzielt günstige Zwischenergebnisse in Phase-1-Studie
(Hinzugefügt: 11.11.2020 um 08:20 Uhr)
https://www.aerzteblatt.de/nachrichten/sw/COVID-19?s=&p=1&n=1&page=1
-
COVID-19-Impfstoffe: Zwischen Vision und Illusion
(Hinzugefügt: 11.11.2020 um 08:15 Uhr)
https://www.aerzteblatt.de/archiv/216359/COVID-19-Impfstoffe-Zwischen-Vision-und-Illusion
-
Forschung an Coronaimpfstoff drückt Biontech tiefer in rote Zahlen
(Hinzugefügt: 11.11.2020 um 08:15 Uhr)
https://www.aerzteblatt.de/nachrichten/118237/Forschung-an-Coronaimpfstoff-drueckt-Biontech-tiefer-in-rote-Zahlen
-
Risiko in CH einem Infizierten zu begegnen
(Hinzugefügt: 10.11.2020 um 08:04 Uhr)
https://www.20min.ch/story/so-gross-ist-das-risiko-einem-infizierten-zu-begegnen-392885003271
-
Brazil suspends Sinovac COVID-19 vaccine trial due to adverse event
(Hinzugefügt: 10.11.2020 um 08:00 Uhr)
https://www.reuters.com/article/us-health-coronavirus-brazil-sinovac-idUSKBN27Q04C
-
Impfstoff von Biontech/Pfizer
(Hinzugefügt: 10.11.2020 um 07:33 Uhr)
https://www.aerzteblatt.de/nachrichten/118189/SARS-CoV-2-Impfstoff-von-Biontech-Pfizer-verhindert-in-Phase-3-Studie-mehr-als-90-der-bestaetigten-Infektionen
-
PFIZER AND BIONTECH
(Hinzugefügt: 09.11.2020 um 17:28 Uhr)
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against
-
nanoparticle vaccines for SARS-CoV-2
(Hinzugefügt: 03.11.2020 um 20:21 Uhr)
https://www.cell.com/cell/pdf/S0092-8674(20)31450-1.pdf?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867420314501%3Fshowall%3Dtrue
-
systematic review of SARS-CoV-2 vaccine candidates
(Hinzugefügt: 03.11.2020 um 08:38 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551521/
-
transverse Myelits
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.rtl.de/cms/corona-impfstoff-britische-studie-wegen-unerwarteter-nebenwirkungen-unterbrochen-4610412.html
-
blog
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://blogs.sciencemag.org/pipeline/archives/2020/09/14/vaccine-transparency
-
russischer Impfstoff
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.spiegel.de/wissenschaft/medizin/corona-russlands-impfstoff-sputnik-v-forscher-finden-hinweise-auf-manipulation-a-a092d1ef-5c32-4527-89cd-7d9d6193270c
-
Impfung
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.aerzteblatt.de/nachrichten/116548/RKI-Kommission-rechnet-mit-mehreren-Coronaimpfstoffen-in-Deutschland
-
Absichtliche Infektionen
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.nature.com/articles/d41586-020-02821-4
-
Fettleibigkeit
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.nature.com/articles/d41586-020-02946-6
-
Immunität
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.nature.com/articles/s41467-020-18450-4
-
Bedenken bei Impfungen
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.nature.com/articles/d41586-020-02706-6
-
BBIBP-CorV
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30831-8/fulltext
-
RNA Impfstoff BioNTech/ Pfizer
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2027906
-
Impfstoff inaktivierte Viren
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.aerzteblatt.de/nachrichten/117524/SARS-CoV-2-Impfstoff-aus-inaktivierten-Viren-in-Phase-1-Studie-auch-bei-aelteren-Menschen-immunogen
-
vaccine efficacy
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://science.sciencemag.org/content/early/2020/10/21/science.abe5938.full
-
Impfung allg
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.aerzteblatt.de/nachrichten/117433/Es-bleibt-abzuwarten-ob-sich-die-Impfstoffe-bei-COVID-19-bewaehren-werden
-
mRNA vaccines
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2770485
-
What defines an efficacious vaccine?
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30773-8/fulltext?utm_campaign=tlcoronavirus20&utm_content=143976734&utm_medium=social&utm_source=twitter&hss_channel=tw-27013292
-
Impfung
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.n-tv.de/wissen/Die-Unwaegbarkeiten-eines-Impfstoffs-article22128809.html
-
248 Impfstoffe
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.aerzteblatt.de/archiv/216359/COVID-19-Impfstoffe-Zwischen-Vision-und-Illusion
-
Astrazeneca
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.tagesschau.de/ausland/astrazeneca-corona-impfstofftest-stop-101.html